Two European companies focused on cell therapies have raised money from private investors: the UK's Cell Medica has raised a £50m series B round, and Belgium's Promethera Biosciences has raised €25.33m in a combination of series C investment and loans and subsidies.
Cell Medica plans to use the cash to progress its lead oncology product, CMD-003, a cell-based treatment in Phase II...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

